Login
$GPCR
$18.56 -$0.01 (0.05%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
Raymond Stevens Also a director
Chief Executive Officer
62 Not stated Not stated $8,429,887
Jun Yoon
Chief Financial Officer
48 Since 2022
4 years
2019 $4,467,595
Matthew Lang
Chief Operating Officer and General Counsel
49 Since 2026
this year
Not stated Not reported
Xichen Lin
Chief Scientific Officer
52 Since 2019
7 years
Not stated $2,480,709
Yingli Ma
Chief Technology Officer
52 Since 2022
4 years
Not stated $1,998,882
Blai Coll
Chief Medical Officer
52 Since 2024
2 years
Not stated $3,246,947
Ashley Hall
Chief Development Officer
54 Since 2024
2 years
Not stated Not reported
Crespo Blas Coll
CHIEF MEDICAL OFFICER
Title from the Form 4 dated Sep 18, 2026
Not stated Not stated Not stated Not reported
John Joseph Berrios
Chief Commercial Officer
Title from the Form 4 dated Aug 6, 2026
Not stated Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
6 of 6
stated in the proxy; 1 not stated
Average tenure
4.0 years
from year joined
CEO also chairs the board
No
Daniel G. Welch
Director Age On board Independent Committees Other public boards 2025 pay Source
Daniel G. Welch
68 Not stated Independent None stated Ultragenyx Pharmaceuticals Inc., Prothena Corporation plc $531,525
Raymond Stevens
62 2019
7 years
Not stated None stated Danaher Corporation Paid as CEO
Ted W. Love
67 2023
3 years
Independent None stated Gilead Sciences, Inc. $357,525
Angus C. Russell
70 2024
2 years
Independent
Audit
Lineage Cell Therapeutics, Inc. $294,806
Sharon Tetlow
66 2022
4 years
Independent None stated None stated $360,025
Eric Dobmeier
57 2022
4 years
Independent None stated Janux Therapeutics, Inc. $352,525
Joanne Waldstreicher
66 2022
4 years
Independent None stated Becton Dickinson and Company $355,025

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed Apr 23, 2026
Entities associated with Avoro
a beneficial owner of greater than 5% of our Ordinary Shares
$14,999,744

Purchase of 4,615,386 Pre-Funded Warrants in the December 2025 follow-on offering, on the same terms as outside investors

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support